Features
Yekaterina Korostash
<i>Bell Atlantic Corp. v. Twombly</i>, a recent Supreme Court decision which addressed the sufficiency of pleadings for a claim under Section 1 of the Sherman Act, has prompted defendants in a wide variety of actions, including patent cases, to file motions urging district courts to apply the 'new' Twombly pleading standard to dismiss the actions against them.
ALM Staff
&
Law Journal Newsletters
&
…
Features
ALM Staff
&
Law Journal Newsletters
&
Highlights of the latest intellectual property news from around the country.
Features
Alex Simonson
Courts and lawyers should pay particular attention to survey findings such as there is 'no likelihood of confusion,' 'there is no likelihood of dilution,' and ensure that the power of the test is high to rely on such conclusions. Anytime a commissioned survey indicates 'no effect,' in addition to issues such as question clarity, randomness of the sample, and other methodological issues, there is the additional critical issue of statistical power.
Features
William I. Schwartz, Paul E. Jahn
&
Aaron P. Rubin
This article discusses the main changes to new version of the GNU General Public License, GPLv3. The new version is the result of extensive public comment and heated debate, and could have far-reaching effects on the use of open source software. GPLv3 is the successor to GPL version 2 (GPLv2), first published in 1991, used extensively today, and among the most popular open source licenses available.
A. Antony Pfeffer
&
John Murray
New methods of stem cell research, such as the recent conversion of skin cells into stem cells, may escape ethical barriers that currently exist in European patent law. In addition to their potential ability to sidestep the ethical barriers to patenting stem cells, these new research approaches can open new scope for researchers to perform stem cell research in the United States.
Zusha Elinson
Patent lawyers started breathing again on Oct. 31, as the specter of new patent rules was chased away ' at least for a little while ' by a Virginia court. U.S. District Judge James Cacheris granted pharmaceutical giant GlaxoSmithKline's motion for a preliminary injunction blocking the U.S. Patent and Trademark Office from implementing rules set to go into effect on Nov. 1.
ALM Staff
&
Law Journal Newsletters
&
…
Features
Matt Berkowitz
Highlights of the latest intellectual property news from around the country.
Features
Alex Simonson
Internet interviewing will undoubtedly become the norm over the next decade. Being familiar with the ways to enhance its reliability and validity will be necessary to create scientifically valid, controlled, and reliable studies that can be used in Lanham Act litigation.
